4Kerenyi L, Kardos L, Sz~isz J, et al. Factors influencing hemorrhagic transformation in ischemic stroke: a clinicopathological comparison[J]. Eur J Neurol, 2006, 13:1251-1255.
5The N1NDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke[J]. Stroke, 2001, 32: 438-441.
6Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasmino- gen activator therapy for acute ischemic stroke in clinical practice: The Multicenter rt-PA Stroke Survey[J]. Circulation, 2002, 105: 1679-1685.
7HsiaAW: "Edwards DF,-Morgenstem LB, et al. Racial disparities in tis- sue plasminogen activator treatment rate for stroke: a population-based study[J]. Stroke, 2011, 42: 2217-2221.
8Hemmen TM, Rapp KS, Emond JA, et al. Analysis of the national in- stitute of neurological disorders and stroke tissue plasminogen activator studies following European Cooperative Acute Stroke Study III patient se- lection criteria[J]. J Stroke Cerebrovasc Dis, 2010, 19: 290-293.
9Wahlgren N, Ahmed N, Eriksson N, et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline da- ta profile in randomized controlled trials: Safe Implementation of Throm- bolysis in Stroke-Monitoring Study(SITS-MOST)[J]. Stroke, 2008, 39: 3316-3322.
10IMS Study Investigators. Hemorrhage in the interventional manage- ment of stroke study[J]. Stroke, 2006, 37:847-851.
